Literature DB >> 15882759

Glutathione S-transferase T1-1 activity upregulated in transitional cell carcinoma of urinary bladder.

T Simic1, J Mimic-Oka, A Savic-Radojevic, M Opacic, M Pljesa, D Dragicevic, M Djokic, R Radosavljevic.   

Abstract

OBJECTIVES: To perform a systematic functional investigation of different glutathione S-transferase (GST) classes, including GST class Theta (GSTT) member GSTT1-1, in transitional cell carcinoma (TCC) and the surrounding normal uroepithelium of the same individuals. Recently, it was suggested that GSTT1-1 might be an important risk modulator for TCC.
METHODS: Tumor samples and surrounding normal uroepithelium were obtained from 24 patients with TCC of urinary bladder. The following substrates with differential specificities were used: 1-chloro-2,4-dinitrobenzene for overall GST activity; 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole for GST Alpha; 1,2-dichloro-4-nitro-benzene for GST Mu; 4-vinylpyridine for GST Pi 1-1(GSTP1-1); and 1,2-epoxy-3-(p-nitrophenoxy)propane for GSTT1-1.
RESULTS: GSTP1-1 and GSTT1-1 activities were demonstrated in all uroepithelial and TCC samples, and GST Mu activity was detectable in 11 of 24 patients. In the tumor specimens, significant upregulation of all expressed GST subtypes was observed. The mean GSTP1-1 and GSTT1-1 level in TCC was increased 2-fold and 3.6-fold, respectively, compared with the mean level in the normal uroepithelium (P <0.001). Tumor GSTT1-1 activities correlated statistically significantly with the tumor stage (P <0.05).
CONCLUSIONS: In tumors and adjacent normal uroepithelium of patients with TCC, three major cytosolic GST classes, Mu, Pi, and Theta, were expressed. Although the GST isoenzyme pattern in TCC was similar to that of the corresponding normal uroepithelium, during cancer progression a clear tendency toward an increase in all the GST subtypes expressed was noted. For the first time, distinct GSTT1-1 activity levels were demonstrated in human uroepithelium, as well as its pronounced upregulation in TCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15882759     DOI: 10.1016/j.urology.2005.01.005

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  10 in total

1.  PharmGKB summary: very important pharmacogene information for GSTT1.

Authors:  Caroline F Thorn; Yuan Ji; Richard M Weinshilboum; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2012-08       Impact factor: 2.089

2.  Upregulated glutathione transferase omega-1 correlates with progression of urinary bladder carcinoma.

Authors:  Tatjana Djukic; Tatjana Simic; Marija Pljesa-Ercegovac; Marija Matic; Sonja Suvakov; Vesna Coric; Dejan Dragicevic; Ana Savic-Radojevic
Journal:  Redox Rep       Date:  2017-03-13       Impact factor: 4.412

Review 3.  Glutathione S-transferases in kidney and urinary bladder tumors.

Authors:  Tatjana Simic; Ana Savic-Radojevic; Marija Pljesa-Ercegovac; Marija Matic; Jasmina Mimic-Oka
Journal:  Nat Rev Urol       Date:  2009-05       Impact factor: 14.432

4.  GSTM1-null and GSTA1-low activity genotypes are associated with enhanced oxidative damage in bladder cancer.

Authors:  Ana Savic-Radojevic; Tatjana Djukic; Tatjana Simic; Marija Pljesa-Ercegovac; Dejan Dragicevic; Tatjana Pekmezovic; Milica Cekerevac; Veljko Santric; Marija Matic
Journal:  Redox Rep       Date:  2013       Impact factor: 4.412

5.  Co-localization of GSTP1 and JNK in transitional cell carcinoma of urinary bladder.

Authors:  Marija Pljesa-Ercegovac; Ana Savic-Radojevic; Tamara Kravic-Stevovic; Vladimir Bumbasirevic; Jasmina Mimic-Oka; Tatjana Simic
Journal:  Genet Mol Biol       Date:  2010-09-01       Impact factor: 1.771

6.  Uroplakin IIIa Is a Marker in Bladder Cancer but Seems Not to Reflect Chemical Carcinogenesis.

Authors:  B Szymańska; M Matuszewski; J Dembowski; R Zdrojowy; A Długosz
Journal:  Biomed Res Int       Date:  2018-07-05       Impact factor: 3.411

7.  Glutathione S-transferase T1, O1 and O2 polymorphisms are associated with survival in muscle invasive bladder cancer patients.

Authors:  Tatjana I Djukic; Ana R Savic-Radojevic; Tatjana D Pekmezovic; Marija G Matic; Marija S Pljesa-Ercegovac; Vesna M Coric; Tanja M Radic; Sonja R Suvakov; Biljana N Krivic; Dejan P Dragicevic; Tatjana P Simic
Journal:  PLoS One       Date:  2013-09-11       Impact factor: 3.240

8.  Does occupational exposure to solvents and pesticides in association with glutathione S-transferase A1, M1, P1, and T1 polymorphisms increase the risk of bladder cancer? The Belgrade case-control study.

Authors:  Marija G Matic; Vesna M Coric; Ana R Savic-Radojevic; Petar V Bulat; Marija S Pljesa-Ercegovac; Dejan P Dragicevic; Tatjana I Djukic; Tatjana P Simic; Tatjana D Pekmezovic
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

9.  Polymorphisms of NRF2 and NRF2 target genes in urinary bladder cancer patients.

Authors:  Edyta Reszka; Zbigniew Jablonowski; Edyta Wieczorek; Ewa Jablonska; Magdalena Beata Krol; Jolanta Gromadzinska; Adam Grzegorczyk; Marek Sosnowski; Wojciech Wasowicz
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-12       Impact factor: 4.553

10.  Urinary Exosomes from Bladder Cancer Patients Show a Residual Cancer Phenotype despite Complete Pathological Downstaging.

Authors:  Stefanie Hiltbrunner; Michael Mints; Maria Eldh; Robert Rosenblatt; Benny Holmström; Farhood Alamdari; Markus Johansson; Rosanne E Veerman; Ola Winqvist; Amir Sherif; Susanne Gabrielsson
Journal:  Sci Rep       Date:  2020-04-06       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.